

Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024

July 30, 2024

CAMBRIDGE, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics. Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report second quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Tuesday, August 6, 2024.

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what's possible in drug discovery. Its DynamoTM platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics' initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow.us.on.Twitter.

Contact:

Megan Goulart 617-545-5526 mgoulart@relaytx.com

Media:

Dan Budwick 1AB 973-271-6085 dan@1abmedia.com